Hims & Hers climbs on potential to sell some unapproved peptides
HIMS•Hims & Hers Health rose 5% to $29.35 after the U.S. health department said it would temporarily allow the sale of some unapproved peptides. The interim policy covers six peptides while regulators consider formally permitting their use in compounded medicines.
1. Temporary peptide policy
Hims & Hers Health shares rose 5% after the U.S. health department said it would temporarily allow the sale of some unapproved peptides. The interim policy covers six compounds, including BPC-157, while regulators decide whether to formally permit their use in compounded medicines.
2. Opportunity remains uncertain
The telehealth firm has said it plans to offer peptides if regulations permit. Leerink analyst Michael Cherny said the move theoretically pulls forward the opportunity by several months at least, but cautioned that the notice is still far from the “green light” Hims & Hers might need to fully capitalize on it.
